Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Liabilities (2016 - 2025)

Tg Therapeutics has reported Other Non-Current Liabilities over the past 10 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $2.1 million for Q4 2025, down 44.56% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 44.56% YoY), and the annual figure for FY2025 was $2.1 million, down 44.56%.
  • Other Non-Current Liabilities for Q4 2025 was $2.1 million at Tg Therapeutics, up from $2.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for TGTX hit a ceiling of $3.8 million in Q4 2024 and a floor of $243000.0 in Q4 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $2.0 million (2025), compared with a mean of $1.7 million.
  • Biggest five-year swings in Other Non-Current Liabilities: tumbled 61.62% in 2021 and later surged 961.62% in 2024.
  • Tg Therapeutics' Other Non-Current Liabilities stood at $360000.0 in 2021, then tumbled by 32.5% to $243000.0 in 2022, then surged by 46.91% to $357000.0 in 2023, then surged by 961.62% to $3.8 million in 2024, then tumbled by 44.56% to $2.1 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $2.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.2 million (Q2 2025) per Business Quant data.